5/3/2019 11:32 AM
H.C. Wainwright just initiated coverage on the drugmaker Collegium Pharmaceutical, Inc (NASDAQ:COLL) with a "buy" rating and a $23 price target -- a roughly 60% upside to the stock's current perch at...
12/5/2017 9:24 AM
Shares of Depomed Inc (NASDAQ:DEPO) are almost 12% higher in electronic trading, after the biotech said it is licensing the sales rights to its opioid pain drugs, Nucynta IR and Nucynta ER, to Colle...